Year
2020
Country
Germany

Highlighting the true burden of sleep apnoea

Sleep apnoea is a potentially serious sleep disorder in which breathing repeatedly stops and starts. For those affected, the impact on quality of life can be profound.

To deepen understanding of the burden of this condition, ResMed has supported to research studies which will be highlighted during MedTech Week. The research shows the importance of effective diagnostic and treatment strategies to minimise the negative health impacts on patients and to maximise cost-effectiveness.

The first paper, published in Lancet Respiratory Medicine, estimates the global prevalence and burden of obstructive sleep apnoea, based on a comprehensive literature review. It reports that almost 1 billion people are affected worldwide, with prevalence exceeding 50% in adults in some countries. It finds that effective strategies are needed to minimise the negative health impacts and to maximise cost-effectiveness.

The second publication concludes that long-term use of continuous positive airway pressure (CPAP) devices reduces mortality, type II diabetes and cardiovascular disease in people with obstructive sleep apnoea–hypopnoea syndrome.

MedTech Week offers an important opportunity to highlight not only the true burden of sleep disorders but the value that medtech innovations can bring to those affected.

October 14, 2020

Germany, France, United Kingdom, Sweden, Norway, Finland, Denmark, Netherlands, Luxembourg, Belgium, Spain, Italy